# AngioDynamics Expands NanoKnife Coverage as Humana Updates Medicare Advantage Policy

- URL: https://stocks.freetheai.org/news/angiodynamics-expands-nanoknife-coverage-as-humana-updates-medicare-advantage-2d8dab
- Published: 2026-10-14T11:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:ANGO](https://stocks.freetheai.org/symbols/NASDAQ-ANGO), [NYSE:HUM](https://stocks.freetheai.org/symbols/NYSE-HUM)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

AngioDynamics, Inc. (NASDAQ:ANGO) announced that Humana Inc. (NYSE:HUM) updated its Medicare Advantage policy to cover irreversible electroporation (IRE) ablation delivered by the NanoKnife System. Effective October 1, 2026, the policy applies medical necessity criteria under Local Coverage Determination L40205 for qualified patients with intermediate-risk prostate cancer and specific liver tumors. In recent trading, AngioDynamics stock moved down 4.39% to $10.90, while Humana shares decreased 3.03% to $420.40.

The policy decision broadens coverage access across Humana's network of approximately 7 million Medicare Advantage members. Reimbursed indications include favorable intermediate-risk prostate cancer and metastatic colorectal cancer in the liver where surgical removal or thermal ablation is not viable. The update builds on previous reimbursement progress, such as the introduction of Category I CPT codes for prostate and liver ablation in January 2026 and Palmetto GBA's coverage policy in July 2026.

Patient access remains subject to Humana's standard prior authorization requirements and individual plan terms. Market participants will follow whether expanded insurer reimbursement accelerates adoption of the NanoKnife device in clinical practice.

## Key points

- Humana Inc. (NYSE:HUM) updated its Medicare Advantage policy effective October 1, 2026, to cover AngioDynamics' NanoKnife IRE technology.
- The coverage applies Local Coverage Determination L40205 medical necessity criteria for intermediate-risk prostate cancer and select liver tumors.
- Humana provides Medicare Advantage coverage to approximately 7 million members across the United States.
- Treatments remain subject to Humana prior authorization requirements and specific plan terms.

## Questions and answers

### What change did Humana make to its coverage for NanoKnife?

Humana updated its Medicare Advantage policy effective October 1, 2026, applying medical necessity criteria under LCD L40205 to cover NanoKnife IRE for eligible prostate and liver cancer patients.

### Which cancer conditions are covered under the updated Humana policy?

Coverage applies to patients with favorable intermediate-risk prostate cancer and metastatic colorectal cancer to the liver that cannot be safely resected or treated with thermal ablation.

### Does Humana coverage guarantee treatment approval for all members?

No, coverage remains subject to Humana's prior authorization requirements and the terms of each member's specific plan.